<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">8610688</journal-id>
<journal-id journal-id-type="pubmed-jr-id">5937</journal-id>
<journal-id journal-id-type="nlm-ta">Mov Disord</journal-id>
<journal-id journal-id-type="iso-abbrev">Mov. Disord.</journal-id>
<journal-title-group>
<journal-title>Movement disorders : official journal of the Movement Disorder Society</journal-title>
</journal-title-group>
<issn pub-type="ppub">0885-3185</issn>
<issn pub-type="epub">1531-8257</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29076559</article-id>
<article-id pub-id-type="pmc">5818145</article-id>
<article-id pub-id-type="doi">10.1002/mds.27196</article-id>
<article-id pub-id-type="manuscript">NIHMS907392</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Genetic Influences on Cognition in Progressive Supranuclear Palsy</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Gerstenecker</surname>
<given-names>Adam</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Roberson</surname>
<given-names>Erik D.</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Schellenberg</surname>
<given-names>Gerard D.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Standaert</surname>
<given-names>David G.</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Shprecher</surname>
<given-names>David R.</given-names>
</name>
<degrees>DO MSci</degrees>
<xref ref-type="aff" rid="A6">6</xref>
<xref ref-type="aff" rid="A7">7</xref>
<xref ref-type="aff" rid="A8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kluger</surname>
<given-names>Benzi M.</given-names>
</name>
<degrees>MD, MS, FAAN</degrees>
<xref ref-type="aff" rid="A9">9</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Litvan</surname>
<given-names>Irene</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A10">10</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Department of Neurology, University of Alabama at Birmingham, Birmingham, AL</aff>
<aff id="A2">
<label>2</label>Alzheimerâ€™s Disease Center, University of Alabama at Birmingham, Birmingham, AL</aff>
<aff id="A3">
<label>3</label>Center for Neurodegeneration,University of Alabama at Birmingham, Birmingham, AL</aff>
<aff id="A4">
<label>4</label>Evelyn F. McKnight Brain Institute, University of Alabama at Birmingham, Birmingham, AL</aff>
<aff id="A5">
<label>5</label>Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA</aff>
<aff id="A6">
<label>6</label>Banner Sun Health Research Institute, Sun City, AZ, USA</aff>
<aff id="A7">
<label>7</label>Department of Neurology, University of Arizona College of Medicine, Phoenix, AZ, USA</aff>
<aff id="A8">
<label>8</label>Department of Neurology, University of Utah, Salt Lake City, UT, USA</aff>
<aff id="A9">
<label>9</label>Department of Neurology, University of Colorado, Aurora, CO, USA</aff>
<aff id="A10">
<label>10</label>Department of Neurosciences, Parkinson and Movement Disorders Center, University of California, San Diego, California, USA</aff>
<author-notes>
<corresp id="FN1">Corresponding Author: Irene Litvan, MD., UC San Diego Department of Neurosciences, Altman Translational Research Institute, 9452 Medical Center Drive, 2W114, La Jolla, CA 92037. Phone: (858) 822-5871, FAX: (858) 822-5743. Email: <email>ilitvan@ucsd.edu</email></corresp>
<fn fn-type="COI-statement" id="FN2">
<p><bold>Relevant conflicts of interest/financial disclosures:</bold> None.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>6</day>
<month>2</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>27</day>
<month>10</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<month>12</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>12</month>
<year>2018</year>
</pub-date>
<volume>32</volume>
<issue>12</issue>
<fpage>1764</fpage>
<lpage>1771</lpage>
<!--elocation-id from pubmed: 10.1002/mds.27196-->
<abstract>
<sec id="S1">
<title>Background</title>
<p id="P1">Cognitive dysfunction is common in progressive supranuclear palsy but the influence of genetics on cognition not been well studied in this disorder.</p>
</sec>
<sec id="S2">
<title>Objective</title>
<p id="P2">To investigate genetic influences on cognition in progressive supranuclear palsy. Specifically, to investigate the effect of genes previously identified as risk alleles, including microtubule-associated protein tau, myelin-associated oligodendrocyte basic protein, eukaryotic translation initiation factor 2-alpha kinase 3, and syntaxin 6, as well as apolipoprotein E, on cognitive function in progressive supranuclear palsy.</p>
</sec>
<sec id="S3">
<title>Methods</title>
<p id="P3">The sample was composed of 305 participants who met criteria for possible or probable progressive supranuclear palsy. Genetic information was determined by TaqMan genotyping assays. A neuropsychological battery was administered to all study participants. Measures included in the battery evaluated for general cognition, executive function, memory, attention, language, and visuospatial ability.</p>
</sec>
<sec id="S4">
<title>Results</title>
<p id="P4">Cognition did not vary significantly between individuals homozygous or heterozygous for the microtubule-associated protein tau H1 haplotype. However, cognition varied significantly at the subhaplotype level, with carriers of the microtubule-associated protein tau rs242557/A allele, which marks the H1c subhaplotype, performing better than non-carriers on measures of general cognitive function, executive function, and attention. No associations were found for other genes.</p>
</sec>
<sec id="S5">
<title>Conclusions</title>
<p id="P5">The results of the current study indicate that variations in microtubule-associated protein tau influence cognition in progressive supranuclear palsy. Although the H1c-specific rs242557/A allele is a risk factor for progressive supranuclear palsy, it may function as a protective factor against cognitive decline for patients with this disorder. Further studies are needed.</p>
</sec>
</abstract>
<kwd-group>
<kwd>progressive supranuclear palsy</kwd>
<kwd>
<italic>MAPT</italic>
</kwd>
<kwd>cognition</kwd>
<kwd>GWAS</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>